[go: up one dir, main page]

AR054560A1 - Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer - Google Patents

Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR054560A1
AR054560A1 ARP060103053A ARP060103053A AR054560A1 AR 054560 A1 AR054560 A1 AR 054560A1 AR P060103053 A ARP060103053 A AR P060103053A AR P060103053 A ARP060103053 A AR P060103053A AR 054560 A1 AR054560 A1 AR 054560A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
beta
phenyl
group
Prior art date
Application number
ARP060103053A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Sunesis Pharmaceuticals Inc filed Critical Merck & Co Inc
Publication of AR054560A1 publication Critical patent/AR054560A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Son inhibidores de la enzima beta-secretasa y que son utiles en el tratamiento de enfermedades en las que está implicada la enzima beta- secretasa, tales como la enfermedad de Alzheimer. Composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos en el tratamiento de enfermedades en las que está implicada la enzima beta-secretasa. Reivindicacion 1: Un compuesto de formula (1) o su tautomero en las que R1 se selecciona del grupo constituido por H, alquilo C1-10, cicloalquilo C3-12, un grupo heterocíclico que tiene 4 a 8 átomos de anillo, en el que un átomo de anillo es un heteroátomo seleccionado del grupo constituido por N. S u O, y fenilo, en el que dicho resto R1 alquilo cicloalquilo, heterocíclico o fenilo está opcionalmente sustituido con uno o más de H, halo, -OH, -CN, -alquilo C1-10, -cicloalquilo C3-12, -O-alquilo C1-10, o fenilo; R2 está opcionalmente presente en uno o más de los átomos de C de anillo, y se selecciona del grupo constituido por halo, -OH, -CN, y -alquilo C1-10; R3 se selecciona del grupo constituido por H, - alquilo C1-10, -cicloalquilo C3-12, fenilo, y heteroarilo, en los que dicho resto R3 alquilo, cicloalquilo, fenilo o heteroarilo está opcionalmente sustituido con uno o más de halo, -OH, -CN, -alquilo C1-10, -cicloalquilo C3-12, -O-cicloalquilo C3-12, -O-alquilo C1-10, y dicho resto alquilo y cicloalquilo está opcionalmente sustituido con uno o más de halo, -OH, -CN, -cicloalquilo C3-12, -alquilo C1-10, o -O- alquilo C1-10, y sales farmacéuticamente aceptables de los mismos, y enantiomeros y diastereomeros individuales de los mismos.
ARP060103053A 2005-07-18 2006-07-17 Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer AR054560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70009005P 2005-07-18 2005-07-18

Publications (1)

Publication Number Publication Date
AR054560A1 true AR054560A1 (es) 2007-06-27

Family

ID=37491690

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103053A AR054560A1 (es) 2005-07-18 2006-07-17 Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer

Country Status (12)

Country Link
US (1) US8211904B2 (es)
EP (1) EP1910364B1 (es)
JP (1) JP2009502786A (es)
CN (1) CN101238124A (es)
AR (1) AR054560A1 (es)
AT (1) ATE550338T1 (es)
AU (1) AU2006270084B2 (es)
CA (1) CA2615656A1 (es)
DO (1) DOP2006000169A (es)
PE (1) PE20070367A1 (es)
TW (1) TW200728305A (es)
WO (2) WO2007011833A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2545765T3 (es) * 2003-02-01 2015-09-15 Janssen Sciences Ireland Uc Inmunización activa para generar anticuerpos para A-beta soluble
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008523815A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
MX2007016182A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
CA2662776A1 (en) * 2006-09-07 2008-03-13 Merck And Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE549923T1 (de) * 2006-10-06 2012-04-15 Merck Sharp & Dohme Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer
EP2091328B1 (en) * 2006-10-30 2011-12-28 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
JP2010515681A (ja) * 2007-01-04 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション アルツハイマー病治療用の二環式スピロピペリジンベータ−セクレターゼ阻害剤
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2146746A4 (en) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
MY160690A (en) 2008-01-18 2017-03-15 Eisai R&D Man Co Ltd Condensed aminodihydrothiazine derivative
ES2375913T3 (es) * 2008-05-05 2012-03-07 Pfizer Inc. Nueva clase de espiropiperidinas para el tratamiento de enfermedades neurodegenerativas.
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en) * 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
CN102209721A (zh) 2008-09-11 2011-10-05 安姆根有限公司 作为β-分泌酶调节剂的螺四环化合物及其使用方法
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US20110224231A1 (en) * 2008-11-23 2011-09-15 Pfizer Inc. Novel Lactams as Beta Secretase Inhibitors
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
MX2012010658A (es) 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
EP2556076A2 (en) 2010-04-09 2013-02-13 Pfizer Inc. Novel sultam compounds
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012100179A1 (en) 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2821401B1 (en) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016139501A1 (en) * 2015-03-04 2016-09-09 Tfchem Gem difluorocompounds as depigmenting or lightening agents
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
JP2023516235A (ja) * 2019-12-03 2023-04-19 キャリーオペ，インク． Ｓｓｔｒ５アンタゴニスト
CN117143004B (zh) * 2023-08-30 2026-01-09 安徽农业大学 一种手性氮杂螺环类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710504A (en) * 1986-04-04 1987-12-01 Merck & Co., Inc. Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
CZ36394A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ATE466014T1 (de) 2001-12-28 2010-05-15 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
BR0309875A (pt) * 2002-05-03 2007-04-10 Israel Inst For Biolog Res Isr métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
US7132568B2 (en) 2002-06-17 2006-11-07 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1554260A1 (en) 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
WO2004050039A2 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
DE60322423D1 (de) * 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
EP1644322A1 (en) 2003-06-16 2006-04-12 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
AU2005295814A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease

Also Published As

Publication number Publication date
AU2006270084B2 (en) 2011-08-25
TW200728305A (en) 2007-08-01
WO2007011833A3 (en) 2007-03-29
JP2009502786A (ja) 2009-01-29
CN101238124A (zh) 2008-08-06
US8211904B2 (en) 2012-07-03
WO2007011833A2 (en) 2007-01-25
EP1910364B1 (en) 2012-03-21
DOP2006000169A (es) 2007-02-28
ATE550338T1 (de) 2012-04-15
CA2615656A1 (en) 2007-01-25
US20070021454A1 (en) 2007-01-25
WO2007011810A1 (en) 2007-01-25
PE20070367A1 (es) 2007-05-12
AU2006270084A1 (en) 2007-01-25
EP1910364A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR063577A1 (es) Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
ECSP088257A (es) Derivados de amida
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR071619A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal